Zinc Oxide
drug drugOn this page
Also known as AnusolC.i. 77947C.i. pigment white 4Ci 77947CurashDr.elsomsPate a l'eauPolano'sSudocremZ.e.b.Zinc (as oxide)Zinc (as zinc oxide)Zinc oxide component of calamineZinc oxide component of vusionZinc oxide emulsionZinc oxide neutralZinc pasteZinc whiteZinci oxydum
Summary
Zinc Oxide (CHEMBL3988900) is an approved small molecule; indicated across 20 conditions including anemia and iron deficiency anemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 20 conditions
- Clinical trials: 17
- Chemistry: 81.4 Da · OZn
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3988900 |
| Name | Zinc Oxide |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 3007857 |
| Molecular formula | OZn |
| Molecular weight | 81.4 |
| InChIKey | RNWHGQJWIACOKP-UHFFFAOYSA-N |
SMILES: [O-2].[Zn+2]
IUPAC name: zinc oxygen(2-)
Also known as: Anusol, C.i. 77947, C.i. pigment white 4, Ci 77947, Curash, Dr.elsoms, Pate a l’eau, Polano’s, Sudocrem, Z.e.b., Zinc (as oxide), Zinc (as zinc oxide)
Patent coverage: 418,117 distinct patent families (991,864 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
12 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| iron deficiency anemia | 4 | MONDO:0001356 | HP:0001891 |
| psoriasis | 4 | MONDO:0005083 | EFO:0000676 |
| sunburn | 4 | MONDO:0005326 | EFO:0003958 |
| burn | 4 | MONDO:0043519 | EFO:0009516 |
| hemorrhoid | 4 | MONDO:0004872 | EFO:0009552 |
| exanthem | 4 | MONDO:0006547 | EFO:1000697 |
| thrombophlebitis | 4 | MONDO:0002800 | HP:0004418 |
| dermatitis | 4 | MONDO:0002406 | MONDO:0002406 |
| skin neoplasm | 4 | MONDO:0002531 | MONDO:0002898 |
| lymphedema | 4 | MONDO:0019297 | MONDO:0019297 |
| neoplasm | 4 | MONDO:0005070 | MONDO:0004992 |
1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| injury | 2 | MONDO:0021178 | EFO:0000546 |
6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 17.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 11 |
| PHASE4 | 2 |
| PHASE2 | 2 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07193849 | PHASE4 | RECRUITING | Zinc Oxide VS MEBO |
| NCT07565181 | PHASE4 | COMPLETED | Effect of Zinc Oxide Ointment on Recurrent Aphthous Stomatitis |
| NCT05157711 | PHASE3 | COMPLETED | Clinical Trial of Anusol Ointment for Symptom Relief in Patients With Haemorrhoids |
| NCT05448937 | PHASE2/PHASE3 | COMPLETED | Lesion Sterilization And Tissue Repair Versus Zinc Oxide And Eugenol For Treatment of Necrotic Primary Molars |
| NCT00376987 | PHASE2 | COMPLETED | Zinc Supplements in Lowering Cadmium Levels in Smokers |
| NCT04505670 | PHASE2 | UNKNOWN | The Effect of Donepezil on Wound Healing |
| NCT07424053 | Not specified | NOT_YET_RECRUITING | Effect of Graphene Oxide on Vital and Non-Vital Primary Teeth Compared to the Conventional Techniques |
| NCT07488416 | Not specified | RECRUITING | Clinical and Radiographic Outcomes of Lesion Sterilization and Tissue Repair Using Zinc Oxide/ 6-gingerol Mix Versus Triple Antibiotic Paste in Non-vital Primary Molars |
| NCT00283660 | Not specified | COMPLETED | Zinc, Mental Health, and School Performance in Guatemalan Schoolchildren |
| NCT01576627 | Not specified | COMPLETED | Zinc Absorption From Zinc Citrate, Zinc Gluconate and Zinc Oxide |
| NCT02255942 | Not specified | COMPLETED | The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate |
| NCT02346188 | Not specified | COMPLETED | Effects of Iron and/or Zinc Supplementation in Mexican School Children Exposed to Lead |
| NCT02714075 | Not specified | COMPLETED | Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Zinc, Citric Acid/Trisodium Citrate and EDTA |
| NCT03309059 | Not specified | COMPLETED | Comparison of Barrier Products in the Prevention of Incontinence-associated Dermatitis in Hospitalized Elderly |
| NCT05420805 | Not specified | COMPLETED | Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Biotics_RTT) |
| NCT05865431 | Not specified | COMPLETED | Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light |
| NCT05898724 | Not specified | COMPLETED | Assessment of the Rate of Oseointegration Surrounding Nano-coated Orthodontic Titanium Miniscrew |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Indicated for: anemia, iron deficiency anemia, psoriasis, sunburn, burn, hemorrhoid, exanthem, thrombophlebitis, dermatitis, skin neoplasm, lymphedema, neoplasm
- In clinical trials for: injury